Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:ESLA NASDAQ:JMAC NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.33-1.3%$2.63$0.49▼$3.62$216.84M1.57875,464 shs410,859 shsESLAEstrella Immunopharma$1.21+0.4%$1.35$0.78▼$3.15$51.20M0.9737,739 shs40,661 shsJMACMaxpro Capital Acquisition$13.53-7.7%$16.26$7.50▼$19.22$181.65M0.0174,040 shs2,322 shsUNCYUnicycive Therapeutics$8.56+0.6%$7.10$3.71▼$11.00$227.22M1.78541,581 shs478,358 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-1.27%0.00%-7.17%+1.30%+194.94%ESLAEstrella Immunopharma+0.42%-5.12%-29.12%-4.37%+21.72%JMACMaxpro Capital Acquisition-7.66%-11.24%-8.16%-32.33%+160.14%UNCYUnicycive Therapeutics+0.59%+8.91%+23.34%+38.06%+53.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$2.33-1.3%$2.63$0.49▼$3.62$216.84M1.57875,464 shs410,859 shsESLAEstrella Immunopharma$1.21+0.4%$1.35$0.78▼$3.15$51.20M0.9737,739 shs40,661 shsJMACMaxpro Capital Acquisition$13.53-7.7%$16.26$7.50▼$19.22$181.65M0.0174,040 shs2,322 shsUNCYUnicycive Therapeutics$8.56+0.6%$7.10$3.71▼$11.00$227.22M1.78541,581 shs478,358 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics-1.27%0.00%-7.17%+1.30%+194.94%ESLAEstrella Immunopharma+0.42%-5.12%-29.12%-4.37%+21.72%JMACMaxpro Capital Acquisition-7.66%-11.24%-8.16%-32.33%+160.14%UNCYUnicycive Therapeutics+0.59%+8.91%+23.34%+38.06%+53.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.88Moderate Buy$6.60183.26% UpsideESLAEstrella Immunopharma 2.00Hold$8.00563.90% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/AUNCYUnicycive Therapeutics 2.67Moderate Buy$24.00180.37% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, CNTX, UNCY, and JMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026UNCYUnicycive Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $37.005/1/2026UNCYUnicycive Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.004/29/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026UNCYUnicycive Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSpeculative Buy$21.00 ➝ $15.004/2/2026UNCYUnicycive Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $40.003/27/2026UNCYUnicycive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026CNTXContext Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/24/2026CNTXContext Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/24/2026CNTXContext Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $7.002/23/2026CNTXContext Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.57 per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/A($0.27) per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics$680K336.11N/AN/A$1.41 per share6.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%N/AESLAEstrella Immunopharma-$13.06M-$0.35N/AN/AN/AN/AN/A-430.91%N/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics-$26.56M-$2.17N/A1.05N/AN/A-134.69%-84.51%N/ALatest ESLA, CNTX, UNCY, and JMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026UNCYUnicycive Therapeutics-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/30/2026Q4 2025UNCYUnicycive Therapeutics-$0.46-$0.82-$0.36-$0.82$0.52 millionN/A3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/18/2026Q4 2025ESLAEstrella Immunopharma-$0.18-$0.01+$0.17-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96ESLAEstrella ImmunopharmaN/A0.120.12JMACMaxpro Capital AcquisitionN/AN/AN/AUNCYUnicycive TherapeuticsN/A2.402.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%ESLAEstrella Immunopharma0.35%JMACMaxpro Capital Acquisition73.18%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%ESLAEstrella Immunopharma55.10%JMACMaxpro Capital Acquisition19.27%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableESLAEstrella ImmunopharmaN/A42.67 million19.16 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableUNCYUnicycive Therapeutics926.70 million23.84 millionNot OptionableESLA, CNTX, UNCY, and JMAC HeadlinesRecent News About These CompaniesUnicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20May 14 at 10:22 PM | msn.comUnicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?May 14 at 10:22 PM | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12 at 7:50 AM | finanznachrichten.deUnicycive Therapeutics Provides Update on FDA Review and Financial Results Ahead of OLC Launch PreparationsMay 12 at 7:30 AM | quiverquant.comQUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12 at 7:05 AM | globenewswire.comUnicycive Therapeutics (UNCY) Projected to Post Earnings on WednesdayMay 6, 2026 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 5, 2026 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street ZenMay 2, 2026 | marketbeat.comB. Riley Financial Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY)May 1, 2026 | marketbeat.comUnicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 16, 2026 | seekingalpha.comUnicycive Therapeutics Inc.April 11, 2026 | barrons.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmApril 9, 2026 | prnewswire.comUnicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comPiper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)April 2, 2026 | theglobeandmail.comUNCY retail buzz explodes 150% this week as traders bet big on experimental drug approvalApril 1, 2026 | msn.comUnicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmMarch 6, 2026 | newsfilecorp.comNImportant Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your BehalfFebruary 17, 2026 | newsfilecorp.comNUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech SummitFebruary 4, 2026 | finance.yahoo.comUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech SummitFebruary 4, 2026 | globenewswire.comUnicycive shares gain as FDA accepts resubmitted OLC NDAJanuary 29, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCathie Wood Is Buying Tesla—Should You?By Sam Quirke | April 15, 2026Tesla’s Earnings Confirm the Shift to AI—But at What Cost?By Sam Quirke | April 23, 2026Tesla’s Cybercab Is Finally Real—But Is It Enough?By Sam Quirke | April 29, 2026TSLA: 3 Reasons the Stock Could Hit $400 in MayBy Sam Quirke | May 5, 2026How Bad Could Tesla’s Cybertruck Recall Be for Shares?By Sam Quirke | May 13, 2026ESLA, CNTX, UNCY, and JMAC Company DescriptionsContext Therapeutics NASDAQ:CNTX$2.33 -0.03 (-1.27%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.33 0.00 (-0.17%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Estrella Immunopharma NASDAQ:ESLA$1.20 +0.01 (+0.42%) Closing price 05/14/2026 03:47 PM EasternExtended Trading$1.21 +0.00 (+0.41%) As of 05/14/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Maxpro Capital Acquisition NASDAQ:JMAC$13.53 -1.12 (-7.66%) As of 05/13/2026Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Unicycive Therapeutics NASDAQ:UNCY$8.56 +0.05 (+0.59%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$8.75 +0.19 (+2.22%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
